REFERENCES
1. Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31:S32-50.
2. Younossi ZM, Stepanova M, Al Shabeeb R, et al. The changing epidemiology of adult liver transplantation in the United States in 2013-2022: the dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease. Hepatol Commun. 2024;8:e0352.
3. Rinella ME, Lazarus JV, Ratziu V, et al.; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542-56.
4. Sohn W, Lee YS, Kim SS, et al.; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025. Clin Mol Hepatol. 2025;31:S1-31.
5. Younossi ZM, Golabi P, Paik J, et al. Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa. Liver Int. 2024;44:1061-70.
6. Lekakis V, Papatheodoridis GV. Natural history of metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:3-10.
7. Sakai K, Shima T, Oya H, et al. Association between liver fibrosis and cause-specific mortality in japanese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a prospective cohort study/liver fibrosis and mortality in Japanese MASLD. Hepatol Res. 2026;56:33-49.
8. Miao L, Targher G, Byrne CD, Cao YY, Zheng MH. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024;35:697-707.
9. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249-53.
10. Sanna C, Rosso C, Marietti M, Bugianesi E. Non-alcoholic fatty liver disease and extra-hepatic cancers. Int J Mol Sci. 2016;17:717.
11. Li AA, Ahmed A, Kim D. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gut Liver. 2020;14:168-78.
12. Bansal SK, Bansal MB. Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity. Aliment Pharmacol Ther. 2024;59:S10-22.
13. Termite F, Archilei S, D’Ambrosio F, et al. Gut microbiota at the crossroad of hepatic oxidative stress and MASLD. Antioxidants. 2025;14:56.
14. DiStefano JK, Gerhard GS. A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease”. Clin Mol Hepatol. 2025;31:297-300.
15. Harrison SA, Bedossa P, Guy CD, et al.; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497-509.
16. Sanyal AJ, Newsome PN, Kliers I, et al.; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-99.
17. Ren Q, Zhi L, Liu H. Semaglutide therapy and accelerated sarcopenia in older adults with type 2 diabetes: a 24-month retrospective cohort study. Drug Des Devel Ther. 2025;19:5645-52.
18. Ayesh H, Beran A, Suhail S, Ayesh S, Niswender K. Efficacy and safety of resmetirom in MASLD and MASH: network meta-analysis of randomized clinical trials. J Basic Clin Physiol Pharmacol. 2025;36:3-11.
19. Huang X, Wu M, Huang B, Zhang Y. Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Front Med. 2025;12:1509947.
20. Kim GA, Jang H, Kim MY, et al. Multicenter prospective cohort study on clinical outcomes and fibrosis patterns in biopsy-proven steatotic liver disease subtypes. Gastroenterology. 2026;170:1571-83.
21. Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet. 2010;11:415-25.
22. Haas ME, Pirruccello JP, Friedman SN, et al. Machine learning enables new insights into genetic contributions to liver fat accumulation. Cell Genom. 2021;1:100066.
23. BasuRay S, Wang Y, Smagris E, Cohen JC, Hobbs HH. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc Natl Acad Sci U S A. 2019;116:9521-6.
24. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461-5.
25. Kozlitina J, Sookoian S. Global epidemiological impact of PNPLA3 I148M on liver disease. Liver Int. 2025;45:e16123.
26. Mahdessian H, Taxiarchis A, Popov S, et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci U S A. 2014;111:8913-8.
27. Liu YL, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:4309.
28. Li XY, Liu Z, Li L, Wang HJ, Wang H. TM6SF2 rs58542926 is related to hepatic steatosis, fibrosis and serum lipids both in adults and children: a meta-analysis. Front Endocrinol. 2022;13:1026901.
29. Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46:352-6.
30. Beer NL, Tribble ND, McCulloch LJ, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet. 2009;18:4081-8.
31. Santoro N, Zhang CK, Zhao H, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology. 2012;55:781-9.
32. Caddeo A, Jamialahmadi O, Solinas G, et al. MBOAT7 is anchored to endomembranes by six transmembrane domains. J Struct Biol. 2019;206:349-60.
33. Thangapandi VR, Knittelfelder O, Brosch M, et al. Loss of hepatic Mboat7 leads to liver fibrosis. Gut. 2021;70:940-50.
34. Thabet K, Asimakopoulos A, Shojaei M, et al.; International Liver Disease Genetics Consortium. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nat Commun. 2016;7:12757.
35. Teo K, Abeysekera KWM, Adams L, et al.; EU-PNAFLD Investigators, GOLD Consortium. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: a meta-analysis. J Hepatol. 2021;74:20-30.
36. Liu S, Gao Y, Zhang C, et al. SAMM50 affects mitochondrial morphology through the association of Drp1 in mammalian cells. FEBS Lett. 2016;590:1313-23.
37. Li Z, Shen W, Wu G, et al. The role of SAMM50 in non-alcoholic fatty liver disease: from genetics to mechanisms. FEBS Open Bio. 2021;11:1893-906.
38. Park JH, Park KJ. Genetic variants associated with metabolic dysfunction-associated fatty liver diseases in a Korean population. Eur J Med Res. 2025;30:318.
39. Hsu SW, Lin MR, Chou WH, Wan YY, Kao WY, Chang WC. Cross-ancestry discovery of genetic risk variants for lean metabolic dysfunction-associated steatotic liver disease. Cell Biosci. 2025;15:131.
40. Chung GE, Lee Y, Yim JY, et al. Genetic polymorphisms of PNPLA3 and SAMM50 are associated with nonalcoholic fatty liver disease in a Korean population. Gut Liver. 2018;12:316-23.
41. Demirtas CO, Yilmaz Y. Decoding 17-beta-hydroxysteroid dehydrogenase 13: a multifaceted perspective on its role in hepatic steatosis and associated disorders. J Clin Transl Hepatol. 2024;12:857-64.
42. Su W, Wu S, Yang Y, et al. Phosphorylation of 17β-hydroxysteroid dehydrogenase 13 at serine 33 attenuates nonalcoholic fatty liver disease in mice. Nat Commun. 2022;13:6577.
43. Abul-Husn NS, Cheng X, Li AH, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med. 2018;378:1096-106.
44. Luukkonen PK, Tukiainen T, Juuti A, et al. Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease. JCI Insight. 2020;5:132158.
45. Dutta T, Sasidharan K, Ciociola E, et al. Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome. Liver Int. 2024;44:1219-32.
46. Emdin CA, Haas ME, Khera AV, et al.; Million Veteran Program. A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. PLoS Genet. 2020;16:e1008629.
47. Koo BK, Joo SK, Kim D, et al. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2018;33:1277-85.
48. Sun B, Ding X, Tan J, et al. TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD. Clin Mol Hepatol. 2024;30:863-82.
49. Paternostro R, Staufer K, Traussnigg S, et al. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease. Hepatol Int. 2021;15:922-33.
50. Gao F, Zheng KI, Chen SD, et al. Individualized polygenic risk score identifies NASH in the Eastern Asia region: a derivation and validation study. Clin Transl Gastroenterol. 2021;12:e00321.
51. Koo BK, Joo SK, Kim D, et al. Development and validation of a scoring system, based on genetic and clinical factors, to determine risk of steatohepatitis in Asian patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2020;18:2592-9.e10.
52. Jamialahmadi O, De Vincentis A, Tavaglione F, et al. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024;30:3614-23.
53. Yoo T, Joo SK, Kim HJ, et al.; Innovative Target Exploration of NAFLD (ITEN) consortium. Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease. J Hepatol. 2021;75:514-23.
54. Hong SE, Mun SJ, Lee YJ, et al. Single-cell eQTL analysis identifies genetic variation underlying metabolic dysfunction-associated steatohepatitis. Nat Genet. 2025;57:1638-48.
55. Xu X, Xu H, Liu X, et al. MBOAT7 rs641738 (C>T) is associated with NAFLD progression in men and decreased ASCVD risk in elder Chinese population. Front Endocrinol. 2023;14:1199429.
56. Young S, Tariq R, Provenza J, et al. Prevalence and profile of nonalcoholic fatty liver disease in lean adults: systematic review and meta-analysis. Hepatol Commun. 2020;4:953-72.
57. Lee Y, Cho EJ, Choe EK, et al. Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population. Sci Rep. 2024;14:9753.
58. Lee J, Cha JH, Cho HS, et al. The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype-phenotype study. J Gastroenterol. 2025;60:1284-95.
59. Ko YK, Kim H, Lee Y, Lee YS, Gim JA. DNA methylation patterns according to fatty liver index and longitudinal changes from the Korean Genome and Epidemiology Study (KoGES). Curr Issues Mol Biol. 2022;44:1149-68.
60. Magdy A, Kim HJ, Go H, et al. DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2024;30:824-44.
61. Ahn J, Kim S, Jeong JY, et al. Whole genome DNA methylation patterns in tissue and cfDNA associated with fibrosis reflect the complex signature of MASLD. PLoS One. 2025;20:e0328207.
62. Sohn HA, Go H, An TH, et al. DNMT1 facilitates the progression of MASLD by impeding transcription mediated by HNF4α and PPARα. Clin Mol Hepatol. 2026;Epub ahead of print.
63. Claveria-Cabello A, Colyn L, Arechederra M, et al. Epigenetics in liver fibrosis: could HDACs be a therapeutic target? Cells. 2020;9:2321.
64. Kang B, Kang B, Roh TY, Seong RH, Kim W. The chromatin accessibility landscape of nonalcoholic fatty liver disease progression. Mol Cells. 2022;45:343-52.
66. Liu CH, Ampuero J, Gil-Gómez A, et al. miRNAs in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2018;69:1335-48.
67. Liu XL, Pan Q, Cao HX, et al. Lipotoxic hepatocyte-derived exosomal microRNA 192-5p activates macrophages through Rictor/Akt/Forkhead box transcription factor O1 signaling in nonalcoholic fatty liver disease. Hepatology. 2020;72:454-69.
68. Tobaruela-Resola AL, Milagro FI, Mogna-Pelaez P, Moreno-Aliaga MJ, Abete I, Zulet MÁ. The use of circulating miRNAs for the diagnosis, prognosis, and personalized treatment of MASLD. J Physiol Biochem. 2025;81:589-609.
69. Kim TH, Lee Y, Lee YS, et al. Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease. Sci Rep. 2021;11:14639.
70. Carpi S, Daniele S, de Almeida JFM, Gabbia D. Recent advances in miRNA-based therapy for MASLD/MASH and MASH-associated HCC. Int J Mol Sci. 2024;25:12229.
71. Kim D, Kim W, Joo SK, et al. Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis. J Gastroenterol. 2020;55:330-41.
72. Son H, Koo BK, Joo SK, et al.; Innovative Target Exploration of NAFLD (ITEN) consortium. PNPLA3 genotypes modify the adverse effect of the total energy intake on high-risk nonalcoholic steatohepatitis development. Am J Clin Nutr. 2023;117:910-7.
73. Smith GI, Shankaran M, Yoshino M, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest. 2020;130:1453-60.
74. Chiu S, Mulligan K, Schwarz JM. Dietary carbohydrates and fatty liver disease: de novo lipogenesis. Curr Opin Clin Nutr Metab Care. 2018;21:277-82.
75. Geidl-Flueck B, Gerber PA. Fructose drives de novo lipogenesis affecting metabolic health. J Endocrinol. 2023;257:e220270.
76. Petersen MC, Shulman GI. Roles of diacylglycerols and ceramides in hepatic insulin resistance. Trends Pharmacol Sci. 2017;38:649-65.
77. Galbo T, Perry RJ, Jurczak MJ, et al. Saturated and unsaturated fat induce hepatic insulin resistance independently of TLR-4 signaling and ceramide synthesis in vivo. Proc Natl Acad Sci U S A. 2013;110:12780-5.
78. Mirza MS. Obesity, visceral Fat, and NAFLD: querying the role of adipokines in the progression of nonalcoholic fatty liver disease. ISRN Gastroenterol. 2011;2011:592404.
79. Schrager MA, Metter EJ, Simonsick E, et al. Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol. 2007;102:919-25.
80. Song W, Yoo SH, Jang J, et al. Association between sarcopenic obesity status and nonalcoholic fatty liver disease and fibrosis. Gut Liver. 2023;17:130-8.
81. Agbaje AO. Accelerometer-based sedentary time and physical activity with MASLD and liver cirrhosis in 2684 British adolescents. npj Gut Liver. 2024;1:2.
82. Wei X, Liu X, Zhao J, Zhang Y, Qiu L, Zhang J. Association of sarcopenia and physical activity on the severity of metabolic dysfunction-associated steatotic liver disease among United States adults: NHANES 2017 - 2018. Front Aging. 2025;6:1573170.
83. Nobili V, Liccardo D, Bedogni G, et al. Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents. Genes Nutr. 2014;9:392.
84. Nishioji K, Mochizuki N, Kobayashi M, et al. The impact of PNPLA3 rs738409 genetic polymorphism and weight gain ≥ 10 kg after age 20 on non-alcoholic fatty liver disease in non-obese japanese individuals. PLoS One. 2015;10:e0140427.
85. O’Hare EA, Yang R, Yerges-Armstrong LM, et al. TM6SF2 rs58542926 impacts lipid processing in liver and small intestine. Hepatology. 2017;65:1526-42.
86. Meroni M, Dongiovanni P, Longo M, et al. Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. EBioMedicine. 2020;52:102658.
87. Tanaka Y, Shimanaka Y, Caddeo A, et al. LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover. Gut. 2021;70:180-93.
88. Fabbrini E, Rady B, Koshkina A, et al. Phase 1 trials of PNPLA3 siRNA in I148M homozygous patients with MAFLD. N Engl J Med. 2024;391:475-6.
89. Sanyal AJ, Taubel J, Badri P, et al. Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis. J Hepatol. 2025;83:838-48.
90. Mak LY, Gane E, Schwabe C, et al. A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. J Hepatol. 2023;78:684-92.
91. Armisen J, Rauschecker M, Sarv J, et al. AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials. J Hepatol. 2025;83:31-42.
92. Li S, Xiong F, Zhang S, et al. Oligonucleotide therapies for nonalcoholic steatohepatitis. Mol Ther Nucleic Acids. 2024;35:102184.
93. Murray JK, Long J, Liu L, et al. Identification and optimization of a minor allele-specific siRNA to prevent PNPLA3 I148M-driven nonalcoholic fatty liver disease. Nucleic Acid Ther. 2021;31:324-40.
94. Eli Lilly and Company. A single-ascending and repeated dose study of ly3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD). Available from: https://trials.lilly.com/en-US/trial/345456. [Last accessed on 18 Jun 2026].
95. ClinicalTrialsgov. A study to learn about the study medicine PF-07853578 and how it acts in the bodies of healthy adults. Available from: https://clinicaltrials.gov/study/NCT05890105. [Last accessed on 18 Jun 2026].
96. Lindén D, Ahnmark A, Pingitore P, et al. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. Mol Metab. 2019;22:49-61.
97. Ciociola E, Dutta T, Sasidharan K, et al. Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation. Clin Mol Hepatol. 2025;31:445-59.
98. Kovooru L, Zhang J, Monni FG, et al. MTARC1 p.A165 ablation reduces hepatocellular carcinoma aggressiveness in vitro and in vivo. Clin Mol Hepatol. 2026;32:829-42.
99. Rodríguez-Sanabria JS, Escutia-Gutiérrez R, Rosas-Campos R, Armendáriz-Borunda JS, Sandoval-Rodríguez A. An update in epigenetics in metabolic-associated fatty liver disease. Front Med. 2021;8:770504.
100. Van Dijck E, Van Laere S, Logie E, et al. Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration. Clin Epigenetics. 2025;17:138.
101. Pant R, Kabeer SW, Sharma S, et al. Pharmacological inhibition of DNMT1 restores macrophage autophagy and M2 polarization in Western diet-induced nonalcoholic fatty liver disease. J Biol Chem. 2023;299:104779.
102. Tapadar S, Fathi S, Wu B, et al. Liver-targeting class I selective histone deacetylase inhibitors potently suppress hepatocellular tumor growth as standalone agents. Cancers. 2020;12:3095.
103. Mannaerts I, Eysackers N, Onyema OO, et al. Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29. PLoS One. 2013;8:e55786.
104. Liu AM, Xu Z, Shek FH, et al. miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma. PLoS One. 2014;9:e86872.
105. Singh R, Ha SE, Wei L, et al. miR-10b-5p rescues diabetes and gastrointestinal dysmotility. Gastroenterology. 2021;160:1662-78.e18.
106. Hanin G, Yayon N, Tzur Y, et al. miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression. Gut. 2018;67:1124-34.
107. Trajkovski M, Hausser J, Soutschek J, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474:649-53.
108. De Vincentis A, Tavaglione F, Jamialahmadi O, et al. A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores. Clin Gastroenterol Hepatol. 2022;20:658-73.
109. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542.
110. Caddeo A, Romeo S. Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease. Clin Mol Hepatol. 2025;31:S76-93.
111. Seagle HM, Akerele AT, DeCorte JA, et al. Genomics-informed drug repurposing strategy identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease. medRxiv 2025;2025.02.18.25321035. Available from: https://www.medrxiv.org/content/10.1101/2025.02.18.25321035v1. [accessed 18 June 2026].
112. Zhou XD, Song SJ, Guo CY, et al. Validation of a data-driven clustering model for MASLD: evidence from three large-scale Asian cohorts. JHEP Rep. 2026;8:101645.
113. Li Z, Luo G, Gan C, et al. Spatially resolved multi-omics of human metabolic dysfunction-associated steatotic liver disease. Nat Genet. 2025;57:3112-25.
114. Thakral N, Desalegn H, Diaz LA, et al. A precision medicine guided approach to the utilization of biomarkers in MASLD. Semin Liver Dis. 2024;44:273-86.
115. Yuan L, Dawka S, Kim Y, et al. Human assembloids recapitulate periportal liver tissue in vitro. Nature. 2026;650:438-49.
116. Pulaski H, Harrison SA, Mehta SS, et al. Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis. Nat Med. 2025;31:315-22.
117. Maghsoudi H, Khonche A, Gereami R, Gharebakhshi F. Physics-aware imaging AI for quantitative MASLD biomarker mapping: a systematic review of deep learning and radiomics across ultrasound, CT, and MRI. Abdom Radiol. 2026;51:2919-31.
118. Kachuri L, Chatterjee N, Hirbo J, et al.; Polygenic Risk Methods in Diverse Populations (PRIMED) Consortium Methods Working Group. Principles and methods for transferring polygenic risk scores across global populations. Nat Rev Genet. 2024;25:8-25.
119. Hoggart CJ, Choi SW, García-González J, Souaiaia T, Preuss M, O’Reilly PF. BridgePRS leverages shared genetic effects across ancestries to increase polygenic risk score portability. Nat Genet. 2024;56:180-6.
